You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
市傳內地醫保談判成功品種藥物降價幅度不逾50%
阿思達克 12-15 14:00
據《央視新聞》報道,今年國家醫保藥品目錄准入談判今日在北京啟動,此次談判為期三天,涉及到癌症、精神疾病、眼病、兒科等藥品品種。昨日上午參與談判的約10家企業中,至少有兩個為中成藥獨家品種,至少一款為糖尿病藥物,至少有3家跨國藥企參與,包括禮來和諾華。

據上午現場消息匯總來看,談判成功的品種下降幅度均未超過50%,去年平均降幅為60.7%。上午基本上是獨家品種,與條件5產品契合度較高。其中,至少有兩個為中成藥獨家品種,至少一款為糖尿病藥物,至少有3家跨國藥企參與,包括禮來和諾華。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account